Skip to main content
AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%

Amgen Lifts 2026 Outlook After Q3 Beat

NEWS

November 3, 2026 at 21:41 UTC

3 min read
Unbranded pill bottles and vials in a biotech lab illustrating strong Q3 results and raised outlook for AMGN

Key Points

  • 01Amgen (AMGN)’s Q3 2026 revenue rose 8% to $10.4 billion, topping estimates
  • 02GAAP EPS grew 19% to $7.08, with adjusted EPS of $6.45 beating forecasts
  • 03Full-year 2026 revenue guidance was raised to $38.9–$39.7 billion
  • 04Non-GAAP EPS guidance increased to $22.90–$23.70 alongside higher GAAP EPS

Amgen lifts 2026 guidance after strong Q3

Amgen (AMGN) raised its full-year 2026 financial guidance after third-quarter results exceeded expectations on both revenue and earnings. The company now expects total 2026 revenue between $38.9 billion and $39.7 billion, with non-GAAP earnings per share projected at $22.90 to $23.70 and GAAP EPS at $18.34 to $19.28. The increased outlook follows an 8% rise in third-quarter revenue to $10.4 billion and stronger profitability metrics compared with the prior year period.

Third-quarter adjusted earnings reached $6.45 per share, beating the average analyst estimate of $5.79, while GAAP earnings per share rose 19% to $7.08. Quarterly revenue of $10.4 billion also came in above a consensus estimate of $10.1 billion, reflecting broad-based growth across the portfolio. Management continues to guide that 2026 share repurchases will not exceed $3.0 billion, and capital expenditures are expected to be about $2.6 billion for the year.

Quarterly revenue, margins and product sales

For the third quarter of 2026, Amgen reported total revenue of $10.4 billion, an 8% increase compared with the same quarter in 2025. Product sales also climbed 8% to $9.883 billion, driven primarily by volume growth across the portfolio. GAAP operating income increased from $2.5 billion to $3.7 billion year over year, while operating margin as a percentage of product sales expanded by 9.9 percentage points to 37.5%.

The company noted that seventeen products delivered at least double-digit sales growth in the quarter, and seventeen products are annualizing at more than $1 billion based on third-quarter sales. Free cash flow for the period was $3.7 billion, compared with $4.2 billion a year earlier. Amgen did not repurchase common stock in the quarter, maintaining flexibility under its full-year repurchase ceiling of $3.0 billion.

Key growth drivers and product performance

Cholesterol treatment Repatha was a major growth driver, with third-quarter sales rising 37% year over year to $1,085 million, primarily on higher volumes. Sales of bone drug Evenity increased 39% to $751 million, while Uplizna revenue grew 191% to $451 million. Newer lung cancer therapy Imdelltra generated sales of $406 million, up 128% from a year earlier, and asthma drug Tezspire recorded a 43% increase to $538 million.

Other notable products also contributed to the top line. Krystexxa sales increased 31% to $419 million, Blincyto rose 27% to $496 million, and Pavblu advanced 41% to $300 million. Amjevita/Amgevita sales grew 24% to $191 million, while Enbrel revenue increased 5% to $611 million. Established products Aranesp, Neulasta and Parsabiv together generated $606 million in third-quarter sales, up 14% year over year, helped by higher net selling prices.

Balance sheet, tax rate and ongoing programs

Amgen reported that its GAAP tax rate decreased by 0.5 percentage points for the third quarter, primarily due to changes in earnings mix, and its non-GAAP tax rate decreased by 2.3 percentage points. The company’s operating margin on a non-GAAP basis increased to 47.3% of product sales. Return on equity stood at 124.14%, with a net margin of 22.95% based on recent results.

The company reaffirmed that total 2026 revenues are expected in the range of $38.9 billion to $39.7 billion as it advances its pipeline, including late-stage programs such as the MariTide Phase 3 trials. Initial results from the broad MariTide Phase 3 program are expected next year, while multiple other Phase 3 studies have either completed enrollment or remain ongoing. Amgen also declared a quarterly dividend of $2.52 per share, equivalent to $10.08 on an annualized basis.

Key Takeaways

  • 01Amgen (AMGN)’s third-quarter beat on both revenue and earnings underpins a higher full-year 2026 outlook for sales and profitability.
  • 02Growth is broad-based, with seventeen products showing double-digit sales gains and seventeen products annualizing at more than $1 billion based on third-quarter sales.
  • 03Improved operating margins and lower tax rates are supporting earnings growth even as the company continues to invest in late-stage programs such as MariTide.

Amgen Lifts 2026 Outlook After Q3 Beat | Trading Dashboard